AstraZeneca to add an additional $136 million investment in Qingdao.

On November 5th, AstraZeneca signed a cooperation agreement with the Management Committee of Qingdao High-tech Industrial Development Zone, announcing an additional investment of approximately $136 million to expand the production capacity of its Qingdao supply base. This expansion will further increase the production capacity of AstraZeneca's inhalable aerosols, better meeting the treatment needs of patients with respiratory system diseases such as asthma and COPD. At the same time, the Qingdao base project also utilizes energy-saving technology to help achieve nearly zero-carbon operations.